The NF-κB signaling is constitutively activated in CLL patients and this activation is known to play an essential role in cancer initiation, progression, and resistance to treatment, through the modulation of a large number of proteins controlling proliferation and apoptosis (Furman et al., 2000; Endo et al., 2007). The gene discussed is NFKB1; the disease is cancer.